Retatrutide does not currently hold a marketing authorisation from the MHRA or EMA and is not legally available as a prescribed medicine in the UK outside of approved clinical trial settings
Lifestyle factors matter
Is it possible we are missing a treatment effect of Lixisenatide because of the heterogeneity present in most Parkinsons groups recruited for clinical trials (in other words Parkinsons is not one disease and we may have recruited a few different subtypes and this watered down the potential effects)
Diabetes Res Clin Pract (2011) 94(3):31121
Amygdala In the amygdala we observed elevated inflammation in response to a WD in females only and GE2 treatment reduced inflammation in males regardless of diet, but increased it in SD-fed females only ( Fig
He L, Wang J, Ping F, Yang N, Huang J, Li Y, Xu L, Li W, Zhang H